Nanjing King-Friend Biochemical Pharmaceutical is a contract manufacturer based in China. It holds 2 active US drug master files across a filed portfolio of 2 molecules. Its filings concentrate with NPRA (MY), EDE (AE) and ARCSA (EC). Its GMP standing is certified by ANVISA (Brazil), MHRA (UK) and US FDA, among 4 authorities. Its most recent recorded inspection, by US FDA, closed on 14 March 2025 as NAI.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Nanjing, United Arab Emirates | Not on file |
| Nanjing, United Arab Emirates | Not on file |
| NANJING, China | Not on file |
| NANJING, China | Not on file |
| China, China | 3004664441 |
| Molecule | Regulators | Docs |
|---|---|---|
| Enoxaparin | US FDA | 1 |
| Heparin Sodium | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| NPRA (MY) | 12 | None |
| EDE (AE) | 2 | None |
| ARCSA (EC) | 2 | None |
| JFDA (JO) | 1 | None |
| UZPHARM (UZ) | 1 | None |
| ANVISA (Brazil) | None | 3 |
| MHRA (UK) | None | 3 |
| US FDA | None | 1 |
| EMA | None | 1 |
Choose your molecules and target markets. Nanjing King-Friend Biochemical Pharmaceutical comes back tiered against every other supplier able to file there.
Start for free